Device data
Health topic Tuberculosis
Respiratory
Classification Diagnosis
Treatment
Scope Clinical trial
Manufacturer
location
Wisconsin, United States

In remote areas and resource-limited settings, clinics may lack expensive, electric nebulizers to induce sputum samples for tuberculosis diagnosis and respiratory treatments.

We have developed two versions of the Human Powered Nebulizer. One is hand-cranked; the other is pedaled like a bicycle. The health care provider operates the HPN while the patient induces a sputum sample or receives treatment. This technology is inexpensive and portable, putting respiratory treatment and diagnostics in the hands of even the most remote clinics.

Demostration

mqdefault.jpgYouTube_icon.svg

Designed by

When and where it was tested/implemented

The first clinical trial was conducted in South African in 2010, in conjunction with the London School of Hygiene and Tropical Medicine and the Desmond Tutu HIV Centre. Additional clinical and field trials are currently being conducted in Malawi and El Salvador.

Funding Source

Funding provided by the Marquette University College of Engineering Opus Fund, the Northwestern University Alumnae Foundation, and the National Collegiate Inventors and Innovators Alliance (a philanthropic competition). Generous in-kind support has been provided by Particle Technology Labs, the London School of Hygiene and Tropical Medicine, the Desmond Tutu HIV Centre, Cape Town, South Africa and the Milwaukee Institute of Art and Design.

Peer-reviewed publication

Other internally generated reports

Externally generated reports

Page data
SDG SDG03 Good health and well-being, SDG09 Industry innovation and infrastructure
Authors Lonny Grafman, Chris Waterguy, Emilio, Kathleen Sienko, Amir Sabet Sarvestani
License CC-BY-SA-3.0
Organizations Appropedia Foundation, University of Michigan
Language English (en)
Related 0 subpages, 1 pages link here
Redirects Human Powered Nebulizer
Views 467 page views (analytics)
Created January 21, 2012 by Evashiu
Last edit September 10, 2026 by Felipe Schenone